Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15888518 | 0.72 | — | — | |
| SCHEMBL23986772 | 0.69 | MAOB (0.32) | — | |
| SCHEMBL62598 | 0.69 | — | — | |
| SCHEMBL6782280 | 0.69 | — | — | |
| SCHEMBL134356 | 0.69 | — | — | |
| SCHEMBL23986824 | 0.68 | TP53 (0.33) | — | |
| SCHEMBL17678920 | 0.67 | ALDH1A1 (0.38) | ALDH1A1MAPK1 | |
| SCHEMBL2738725 | 0.67 | — | — | |
| SCHEMBL3439787 | 0.67 | ALDH1A1 (0.38) | ALDH1A1MAPK1 | |
| SCHEMBL12888006 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858387-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seagen Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2020-11-05 | — | — | US | disclosed |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190338045-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2019-11-07 | — | — | US | disclosed |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| EP-3434275-A1 | ASSAY FOR CANCER CELLS BASED ON THE USE OF AURISTATIN CONJUGATES WITH ANTIBODIES | Seattle Genetics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2018-05-10 | — | — | US | disclosed |
| EP-3120861-A1 | INTERMEDIATE FOR CONJUGATE PREPARATION COMPRISING AURISTATIN DERIVATIVES AND A LINKER | Seattle Genetics, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. | 2017-01-05 | — | — | US | disclosed |
| EP-2478912-B1 | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy | SEATTLE GENETICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005023762-A1 | PYRROLIDINE-2-CARBONITRILE DERIVATIVES AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-0758327-B1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | ALDH1A1 3456/4885MAPK1 3536/4885 |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | ALDH1A1 2289/4885MAPK1 3839/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | ALDH1A1 437/4885MAPK1 464/4885 |
| US-20190338045-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | ALDH1A1 3456/4885MAPK1 3536/4885 |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | MMAB, CAD, VIM | ALDH1A1 3456/4885MAPK1 3536/4885 |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | CAD, MMAB, AURKC | ALDH1A1 4361/4885MAPK1 3523/4885 |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | MMAB, CAD, VIM | ALDH1A1 3456/4885MAPK1 3536/4885 |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | ALDH1A1 3456/4885MAPK1 3536/4885 |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | ALDH1A1 3456/4885MAPK1 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.